eLearning Modules
Management of advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer: a patient case study
Presented by Laura Fugazzola, Italy
Learn more about when to initiate systemic therapy in patients with advanced RAI-refractory DTC and the targeted therapy options available for different types of molecular alterations.
Management of advanced medullary thyroid cancer: a patient case study
Presented by Lori J Wirth, USA
Learn more about the optimal molecular testing methods for patients with advanced MTC, how to choose a suitable targeted therapy, and the clinical evidence and international guidelines supporting their use.
These interactive patient case studies will help you understand the options available for molecular testing and targeted therapy in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and advanced medullary thyroid cancer (MTC). Laura Fugazzola and Lori J Wirth will provide expert guidance on how to choose a systemic therapy based on the results of molecular tests, drawing on clinical evidence and international guideline recommendations.
Learning Objectives
After participating in Management of advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer: a patient case study and/or studying its content, learners will be able to:
- Determine the most suitable option for targeted therapy in patients with RAI-refractory DTC based on molecular test results
- Describe the clinical data and guideline recommendations supporting the use of targeted therapies in RAI-refractory DTC
After participating in Management of advanced medullary thyroid cancer: a patient case study and/or studying its content, learners will be able to:
- Select the optimal molecular testing method for patients with advanced MTC
- Determine the most suitable targeted therapy option for patients with advanced MTC based on clinical evidence and guideline recommendations
Meet the Experts
Lori J Wirth
Medical Director,
Head and Neck Oncology Program,
Massachusetts General Hospital, Boston, USA
Born in Milan in 1964, Professor Laura Fugazzola holds the position of full Professor of Endocrinology at the University of Milan, Italy. She is head of the Center of Excellence in the diagnosis and treatment of thyroid cancer at the Istituto Auxologico Italiano IRCCS, Milan and is also Investigator or Principal Investigator for phase 3 clinical trials (Lenvatinib, Vandetanib, Cabozantinib and Selpercatinib) for advanced differentiated and medullary thyroid cancers.
Professor Fugazzola’s main areas of scientific interest are molecular biology studies in differentiated and medullary thyroid cancer, studies on tumoral markers useful for the diagnosis and follow-up of patients with thyroid cancer, and clinical and epidemiological analyses of risk factors for thyroid tumors. She is a member of several national and international societies and Editor of a number of journals: The European Journal of Endocrinology, The Journal of Clinical Endocrinology & Metabolism, and The Journal of Endocrinological Investigation. Professor Fugazzola has been a member of the International Thyroid Oncology Group (ITOG) since 2015 and is President Elect of the European Thyroid Association. She has acted as reviewer for several international journals and has published 198 papers in peer-reviewed journals.
Disclosures
Laura Fugazzola has received honoraria and/or consultation fees from Eisai, Lilly and Ipsen.
Dr Lori Wirth is the Elizabeth and Michael Ruane Endowed Chair of Medical Oncology, Medical Director of the Center for Head and Neck Cancers at the Massachusetts General Hospital Cancer Center and an Associate Professor in Medicine at Harvard Medical School. She joined Massachusetts General Hospital in 2008. She also holds an appointment at the Massachusetts Eye and Ear Infirmary and is co-director of the Massachusetts General/Mass Eye and Ear Advanced Thyroid Cancer Clinic.
Dr Wirth is a leading authority in advanced thyroid cancer and head and neck oncology, with special expertise in combined modality therapy for cancers of the head and neck, immunotherapy and molecularly targeted therapies for thyroid cancer. Her research focuses on clinical trials and leveraging translational data to maximize the impact of clinical trial outcomes.
Beyond Massachusetts General, Dr Wirth is the former Chairperson of the International Thyroid Oncology Group (ITOG), is a founding Executive Committee member of Thyroid International Recommendations Online (TIRO) and sits on a number of other national and international oncology committees, including the American Thyroid Association Guidelines Committee, the National Comprehensive Cancer Network’s Thyroid Cancer Committee and the ABIM’s Medical Oncology Board Examination Committee.
Disclosures
Dr Wirth has received honoraria for advisory roles from: Bayer HealthCare Pharmaceuticals; Coherus; Curie Therapeutics; Eli Lilly; Eisai; Exelixis; Genentech USA; Merck; Morphic Therapeutics and Tome Biosciences. She has also received honoraria for serving on a data safety monitoring board for PDS Biotechnology Corporation.
Professor Elisei holds the position of Associate Professor of Endocrinology in the Department of Endocrinology, Pisa University, Italy.
After completing her medical training at the University of Pisa, Professor Elisei studied a speciality degree in Endocrinology before completing several Postdoctoral Research projects both in Belgium and the US, working in the area of endocrinology and metabolism.
She has won numerous professional awards for her work. In 2018, she won the European Thyroid Association (ETA) award as a distinguished scientist and in recognition of her outstanding contribution to thyroid research. In 2020, in recognition of scientific merit in thyroid cancer research, she was awarded the title ‘Commendatore’ by the President of the Italian Republic. Most recently, in 2021, she was awarded the British Thyroid Association ‘George Murray’ lectureship for fundamental contributions to the advancement of knowledge in the field of pathophysiology and therapy of thyroid disease.
Professor Elisei has authored more than 300 papers in peer-reviewed journals, over 60 manuscripts in meetings’ proceedings and book chapters and more than 500 Abstracts for national and international meetings. She is also Principal Investigator in twenty Phase II or III clinical trials on drugs for medullary and dedifferentiated thyroid cancer treatment.
Disclosures
Professor Elisei has received honoraria or consultation fees from: Eisai, Ipsen, Bayer, Lilly and Roche.
Planning Committee
In addition to the expert faculty, Springer Healthcare IME planners and staff include Jaia Barratt and Leah Bundy. The Planning Committee have no financial relationships to disclose.
